Disease relevance of EHBP1

• Patients with Paget's disease of bone were treated with oral disodium dihydrogen ethylidene-1-hydroxy-1,1-bisphosphonate (EHBP), a drug that is known to stimulate renal tubular reabsorption of orthophosphate (Pi) [1].
• CONCLUSIONS: EHBP has the advantage of clinical acceptance as a therapeutic agent for other purposes and its toxicity has been well studied [2].

High impact information on EHBP1

• Moreover, EHD1 is shown to interact through its EH domain with the protein EHBP1, which is also required for insulin-stimulated GLUT4 movements and hexose transport [3].
• Here we identified two novel proteins denoted EH domain protein 2 (EHD2) and EHD2-binding protein 1 (EHBP1) that link clathrin-mediated endocytosis to the actin cytoskeleton [4].
• Role of EHD1 and EHBP1 in perinuclear sorting and insulin-regulated GLUT4 recycling in 3T3-L1 adipocytes [3].
• Thus EHD2 appears to connect endocytosis to the actin cytoskeleton through interactions of its N-terminal domain with membranes and its C-terminal EH domain with the novel EHBP1 protein [4].
• EHD2 localizes with cortical actin filaments, whereas EHBP1 contains a putative actin-binding calponin homology domain [4].

Chemical compound and disease context of EHBP1

• Both CBMIDA and EHBP were effective in excreting DU, reducing DU concentrations in organs, and preventing DU-induced toxicity, and CBMIDA was superior to EHBP, particularly in the prevention of renal dysfunction [5].

Biological context of EHBP1

• In a series of experiments with animals the effectiveness of various preparations and treatment plans was compared Action of 1-hydroxyethyliden-1, 1-bisphosphonic acid (EHBP, xydiphon) on calcium metabolism and bone tissue in human was the subject of experiments with long-term head-down tilt (HDT) [6].

Anatomical context of EHBP1

• After 2 weeks of oral EHBP, the increase in the Pi concentration in patients' erythrocytes was 31% compared with 64% in plasma [1].
• It is therefore unlikely that this effect is due to an immediate action of EHBP on the luminal face of the renal brush border Pi transporter [1].
• These cells were seeded onto slices of human dentin which had been soaked in either saline (control), or solutions of 10(-5) M 1-hydroxyethylidene-1, 1-bisphosphonic acid (EHBP), 10(-6) M dichloromethylene bisphosphonic acid (Cl2MBP), or 10(-6) M gallium nitrate [7].

Associations of EHBP1 with chemical compounds

• Recently, the focus has turned to drugs that have been used successfully in the treatment of a variety of other diseases, for example the iron chelating drug deferiprone or 1,2-dimethyl-3-hydroxypyrid-4-one (L1), which is used in thalassaemia and ethane-1-hydroxy-1,1-bisphosphonate (EHBP), which is used in osteoporosis [8].
• RESULTS: The present study shows that one prompt injection of EHBP reduced uranium deposition in kidneys by a factor of five after acute intramuscular contamination in rats [2].
• MATERIALS AND METHODS: The efficacy of ethane-1-hydroxy-1,1-bisphosphonate (EHBP), already in use as a therapeutic agent, was investigated in animal experiments [2].
• Local treatments by EHBP seemed more efficient than those by DTPA in decorporating uranium and plutonium but the complexes radionuclide-EHBP seemed to diffuse through the skin more than the radionuclide-DTPA complexes if the skin was not rinsed after application of the chelating agent [9].
• One group was kept as the control (no injected DU) group, which consisted of five intact, five with CBMIDA, and five with EHBP administration [5].

Other interactions of EHBP1

• High expression of EHD2 or EHBP1 in intact cells mediates extensive actin reorganization [4].

Analytical, diagnostic and therapeutic context of EHBP1

• Intravenous EHBP caused a more rapid increase in plasma Pi, but maximum hyperphosphatemia was not observed until 7-11 days after treatment commenced [1].

References